Lexeo completes IPO raising $111.5M; Q3 net loss $20.1M as programs advance

Lexeo Therapeutics, Inc.

IPO in November 2023 raised $111.5M gross; pro forma cash $136.4M, funding operations into Q4 2025.
Completed enrollment of all four cohorts in LEAD Phase 1/2 trial of LX1001 for APOE4-Alzheimer's.
Received Canadian CTA clearance for LX2006 (FA cardiomyopathy); first non-US site activated.
Net loss Q3 2023: $20.1M ($12.36 per share) vs $17.1M ($10.38) in Q3 2022; R&D spend $17.2M.
Sandi See Tai, M.D. joined as SVP Clinical Development and Operations in October 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

Lexeo Therapeutics, Inc. reported financial results for the three and nine-months ended September 30, 2023.

Period: the three and nine-months ended September 30, 2023
Result: reported results

Exact text from the filing

On December 11, 2023, Lexeo Therapeutics, Inc. (the " Registrant ") issued a press release announcing business highlights and its financial results for the three and nine-months ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-069193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.